Patents Assigned to IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
  • BREAST CANCER THERAPEUTICS
    Publication number: 20190030161
    Abstract: The present invention relates to a method of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of a RANKL inhibitor to said patient.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef PENNINGER, Daniel SCHRAMEK
  • BREAST CANCER DIAGNOSTICS USING RANKL AND OPG
    Publication number: 20170102388
    Abstract: The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.
    Type: Application
    Filed: December 27, 2016
    Publication date: April 13, 2017
    Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Josef PENNINGER, Daniel SCHRAMEK, Georg SCHETT, Martin WIDSCHWENDTER, Ian J. JACOBS, Usha MENON
  • Archease as RNA ligaes complex member
    Patent number: 9296994
    Abstract: The present invention relates to the use of Archease proteins as RNA ligase enhancer, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: March 29, 2016
    Assignee: IMBA-INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Johannes Popow, Javier Martinez, Anne Nielsen, Alexander Schleiffer, Theresa Henkel
  • HAPLOID CELLS
    Publication number: 20140342369
    Abstract: The present invention relates to the generation of stable haploid cell cultures, uses of said cells in forward and reverse genetics, especially the identification of target genes associated with a modified phenotype and in particular identifying genetic targets associated with toxin resistance, especially ricin toxicity resistance, and therapeutic uses of target compounds.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 20, 2014
    Applicant: IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH
    Inventors: Ulrich Elling, Josef Penninger, Jasmin Taubenschmid